Context Therapeutics is trading 5.31% down at $0.26; no clear company-specific catalyst was identified for the October 14 decline. - A report published October 14 noted that Zacks Research downgraded its rating from hold to strong sell. The rating was issued Monday and was not linked to the current move. - XBI was down 2.01% during the regular session, offering sector context but not a confirmed explanation for the larger decline.